The latest results from the STAMPEDE trial have shown immediate radiotherapy with standard hormone therapy could increase the survival of thousands of men diagnosed with advanced prostate cancer that hasn't spread too widely. We're now calling for the treatment to be offered to these men as standard on the NHS.
Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.
BLOG: Our CEO gives her thoughts on what new research could mean for treating prostate cancer and how Prostate Cancer UK is working to make the most of it.
Announced by researchers at a cancer conference in Chicago, the new findings show earlier and combined use of existing treatments can have a significant impact on advanced disease, but questions remain about its suitability for all men.
Following months of intense pressure from us, clinicians and patients, NHS England finally announces that men with newly diagnosed advanced prostate cancer will now be offered immediate access to chemotherapy that could extend their lives by an average of 15 months.
With the successful STAMPEDE trial now officially published in the Lancet, we call for upfront docetaxel treatment for men with advanced prostate cancer to be adopted across NHS England without further delay.
BLOG: We were about to go large on the NHS's continued lack of action overs the positive results of STAMPEDE. All our campaigning machinery was set to whirl into motion. And then a sudden U-turn left us both delighted and eager to prevent similar treatments from experiencing such delays in the future, writes Karen Stalbow.
While many hospitals delay putting into action the staggering results of the STAMPEDE trials, more than 500 men a month are missing the chance to extend their lives. We talked to one of them.
BLOG: Dr Iain Frame, our Director of Research, on how the STAMPEDE trial shows why accelerated access matters and how he thinks it can be achieved.
Men with advanced prostate cancer were found to live up to 17 months longer with docetaxel chemotherapy in addition to hormone therapy in the latest results from the CHAARTED clinical trials, fuelling demands for the NHS to make the affordable treatment the norm in the UK.